TCR2 Therapeutics Inc. Stock News

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from s

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial; dat

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering fro

SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday. Deutsche Bank lowered Adobe Inc. (NASDAQ: A

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffer

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering fro

CAMBRIDGE, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering fro

In last trading session, TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw 0.52 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.86 trading at $0.05 or 1.78% at ring of the bell on the day assigns it a market valuation of $119.55M. That closing price of TCRR’s stock is … Analysts Predict TCR2 Therapeutics Inc. (NASDAQ:TCRR) To Reach $29.00 In 12 Months Read More »

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients sufferi

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering

Tcr2 Therapeutics Inc (TCRR) shares closed today at 1.0% above its 52 week low of $3.87, giving the company a market cap of $149M. The stock is currently down 16.1% year-to-date, down 88.5% over the past 12 months, and down 74.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 58.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 6595.3% The company's stock price performance over the past 12 months lags the peer average by 458.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.